Many investigators have reported other potential molecular markers for this cancer, including the following: overexpression of human kallikrein-related peptidase 2 (hK2), early prostate cancer antigen (EPCA), α-methylacyl-coA racemase (AMACR), insulin-like growth factors and binding proteins (IGFBP-2 and IGFBP-3), TGF-β1, elevated circulating levels of the cytokine interleukin-6 (IL-6) and its receptors, urokinase plasminogen activator (uPA) and receptor (uPAR), enhancer of zeste homolog 2 (EZH2), and prostate-specific membrane antigen (PSMA) [96,97,98,99,100,101,102,103]. This evidence concerns the gene EZH2 and cancer.